Sino Biopharmaceutical (HKG:1177) said China's National Medical Products Administration approved Loxoprofen Sodium Cataplasms for marketing, according to a Friday filing with the Hong Kong bourse.
The drug has anti-inflammatory and analgesic qualities and is used for treating diseases and symptoms, including osteoarthritis, muscle pain, and swelling and pain due to injuries, the filing added.